Impax Asset Management Group plc Purchases 80,545 Shares of Intuitive Surgical, Inc. $ISRG

Impax Asset Management Group plc grew its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 60.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 213,773 shares of the medical equipment provider’s stock after purchasing an additional 80,545 shares during the period. Impax Asset Management Group plc’s holdings in Intuitive Surgical were worth $95,606,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Tobam raised its stake in Intuitive Surgical by 666.7% during the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 40 shares during the period. Kilter Group LLC bought a new stake in shares of Intuitive Surgical in the second quarter worth about $27,000. Greykasell Wealth Strategies Inc. bought a new stake in shares of Intuitive Surgical in the third quarter worth about $27,000. Princeton Global Asset Management LLC acquired a new stake in shares of Intuitive Surgical during the second quarter worth about $30,000. Finally, Guerra Advisors Inc acquired a new stake in shares of Intuitive Surgical during the third quarter worth about $37,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Trading Up 0.5%

Intuitive Surgical stock opened at $495.15 on Wednesday. The company has a market cap of $175.84 billion, a P/E ratio of 62.76, a price-to-earnings-growth ratio of 3.83 and a beta of 1.65. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $609.08. The company has a fifty day simple moving average of $546.68 and a 200 day simple moving average of $510.62.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, topping the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The firm had revenue of $2.87 billion for the quarter, compared to analysts’ expectations of $2.72 billion. During the same period in the previous year, the firm posted $2.21 EPS. The company’s revenue for the quarter was up 18.8% on a year-over-year basis. On average, equities research analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Buying and Selling

In other Intuitive Surgical news, Director Gary S. Guthart sold 2,800 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $531.52, for a total transaction of $1,488,256.00. Following the transaction, the director owned 15,720 shares of the company’s stock, valued at $8,355,494.40. The trade was a 15.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Myriam Curet sold 126 shares of the company’s stock in a transaction that occurred on Thursday, January 29th. The stock was sold at an average price of $520.02, for a total value of $65,522.52. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 55,530 shares of company stock worth $30,459,295. Corporate insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

ISRG has been the subject of several research analyst reports. The Goldman Sachs Group reiterated a “buy” rating and issued a $714.00 price objective on shares of Intuitive Surgical in a research report on Friday, January 9th. Piper Sandler reiterated an “overweight” rating and issued a $620.00 price target (up previously from $610.00) on shares of Intuitive Surgical in a report on Friday, January 23rd. HSBC raised their price objective on shares of Intuitive Surgical from $644.00 to $653.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Barclays set a $712.00 price objective on shares of Intuitive Surgical and gave the company an “overweight” rating in a research report on Monday, January 26th. Finally, Sanford C. Bernstein lifted their price target on Intuitive Surgical from $740.00 to $750.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $617.23.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.